Fulvestrant: as the comparator
29 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- A Study of Single Dose of BL0175 in Postmenopausal WomenNot yet recruitingNCT07366632Phase 1Report a problem
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingNCT07354022Phase 3Report a problem
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingNCT07024173Phase 3Report a problem
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingNCT06979596Phase 2Report a problem
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerRecruitingNCT06954961Phase 3Report a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingNCT06837792Phase 2Report a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3Report a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingNCT06486883Phase 2Report a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3Report a problem
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingNCT06176534Phase 2Report a problem
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingNCT05472792Phase 2Report a problem
- Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingNCT05181033Phase 2Report a problem
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingNCT05654623Phase 3Results postedReport a problem
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results postedReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingNCT04576455Phase 2Results postedReport a problem
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingNCT04214288Phase 2Results postedReport a problem
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedNCT04059484Phase 2Results postedReport a problem
- Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3Results postedReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results postedReport a problem
- A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) TherapyTerminatedNCT02569801Phase 2Results postedReport a problem
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingNCT06680921Phase 3Report a problem
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnNCT06585969Phase 3Report a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Phase 3Report a problem
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingNCT06016738Phase 3Report a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingNCT05306340Phase 3Report a problem
- Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerTerminatedNCT05065411Phase 3Report a problem
- Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationCompletedNCT03781063Phase 2Report a problem
- Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.CompletedNCT03236974Phase 1Report a problem
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast CancerStatus unknownNCT03024580Phase 2Report a problem